The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

Summary Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was t...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2020-12, Vol.191 (5), p.738-747
Hauptverfasser: Kimby, Eva, Lockmer, Sandra, Holte, Harald, Hagberg, Hans, Wahlin, Björn E., Brown, Peter, Østenstad, Bjørn
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Age Factors
Aged
Aged, 80 and over
chemo-free regimen
Chemotherapy
Clinical trials
Disease-Free Survival
Female
follicular lymphoma
Hematology
Humans
Immunotherapy
Interferon
Lymphoma
Lymphoma, Follicular - drug therapy
Lymphoma, Follicular - mortality
Male
Medicin och hälsovetenskap
Middle Aged
Monoclonal antibodies
prognosis
Risk Factors
Risk groups
Rituximab
Rituximab - administration & dosage
Rituximab - adverse effects
Survival Rate
Targeted cancer therapy
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Summary Follicular lymphoma (FL) is a heterogeneous disease; therefore, reliable prognostic tools are needed to plan treatment strategies. The FL International Prognostic Index (FLIPI) was developed before the rituximab era, while the PRIMA‐PI was built on rituximab chemotherapy. Our objective was to evaluate these two prognostic tools in a cohort of 291 patients with FL treated in two prospective randomised Nordic Lymphoma Group trials with rituximab ± interferon. All patients had symptomatic/progressive disease and were previously untreated. The PRIMA‐PI was prognostic for both time to treatment failure (TTF) and overall survival (OS) (log‐rank P = 0·003 and P 
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.16692